Dianthus Therapeutics
DNTH
94 hedge funds and large institutions have $217M invested in Dianthus Therapeutics in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 16 reducing their positions, and 18 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.24% less ownership
Funds ownership: 4.39% → 4.14% (-0.24%)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
1% less funds holding
Funds holding: 95 → 94 (-1)
12% less capital invested
Capital invested by funds: $248M → $217M (-$30.4M)
97% less call options, than puts
Call options by funds: $3K | Put options by funds: $89K
Top Buyers
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$7.1M |
| 2 |
Two Sigma Advisers
New York
|
+$1.38M |
| 3 |
Two Sigma Investments
New York
|
+$1.3M |
| 4 |
BlackRock
New York
|
+$1.23M |
| 5 |
Renaissance Technologies
New York
|
+$1.13M |
Top Sellers
| 1 |
Alkeon Capital Management
New York
|
-$4.51M |
| 2 |
AG
Artal Group
Luxembourg
|
-$3.38M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.38M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$3.11M |
| 5 |
LM
Luminus Management
Houston,
Texas
|
-$2.7M |
DNTH Hedge Fund Activity: Q3 2020 in Review
94 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2020, worth a combined $217M — down 12% from $248M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of DNTH and 17 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 34 added.
The largest buyer was Aquilo Capital Management, opening a new position worth an estimated $7.1M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $4.51M sold.
- 94 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2020, down from 95 in Q2 2020.
- Funds reported $217M of Dianthus Therapeutics stock for Q3 2020, down 12% quarter-over-quarter.
- 17 funds opened new Dianthus Therapeutics positions in Q3 2020 and 18 closed out, a net change of -1 holder.
- The largest Dianthus Therapeutics buyer in Q3 2020 was Aquilo Capital Management, an estimated $7.1M added.
- The largest Dianthus Therapeutics seller in Q3 2020 was Alkeon Capital Management, an estimated $4.51M sold.
Based on aggregated 13F filings for Q3 2020.